Contact Information: For further information contact: Fern Lazar/David Carey Lazar Partners Ltd. 1-866-GIVEN-IR /
Given Imaging Announces Conference Call to Review PillCam(R) SB Video Capsule and Bravo(R) pH Monitoring System Abstract Highlights at Digestive Disease Week
Call Scheduled for Wednesday, June 3 at 11:00am CT, 12:00pm ET
| Source: Given Imaging
YOQNEAM, ISRAEL--(Marketwire - May 29, 2009) - Given Imaging (NASDAQ : GIVN ) today
announced that the company will host a conference call on June 3, 2009 to
review PillCam SB video capsule and Bravo pH Monitoring System abstracts
presented at Digestive Disease Week 2009 taking place May 30 - June 4 in
Chicago. Deborah Mutter, Given Imaging's Corporate Manager, Clinical
Marketing, will be joined by Dr. Ian M. Gralnek, Head, GI Outcomes Unit and
Senior Physician Department of Gastroenterology Rambam Health Care Campus
in Haifa, Israel, and Dr. John Pandolfino, Professor of Medicine, Feinberg
School of Medicine, Northwestern University. The call will take place at
11:00am CT, 12:00pm ET.
To participate in this teleconference, please dial 888-224-1065 fifteen
minutes before the conference is scheduled to begin. Callers outside of
the U.S. should dial 913-312-1438. The call will also be webcast live at
www.givenimaging.com. A replay of the call will be available for two weeks
on the company's website, or until June 24 by dialing 888-203-1112. Callers
outside of the U.S. should dial 719-457-0820. The replay participant code
is 1724821.
About Given Imaging Ltd.
Since 2001 Given Imaging has advanced gastrointestinal diagnosis by
developing innovative, patient-friendly tools based on its PillCam®
Platform. PillCam capsule endoscopy provides physicians with natural images
of the small intestine via PillCam SB, the esophagus through PillCam ESO
and the colon with PillCam COLON [not cleared for use in the USA]. The
PillCam capsules are miniature video cameras that patients ingest. Given
Imaging's other capsule products include Agile™ patency capsule, to
verify intestinal patency, and Bravo®, the only wireless, catheter-free,
48-hour pH test commercially available for pH testing to assess
gastroesophageal reflux disease (GERD). Given Imaging's products use
cutting-edge wireless technology and advanced software to enable
gastroenterologists to better diagnose and more accurately treat patients.
All Given Imaging products allow patients to maintain normal activities.
Given Imaging's headquarters, manufacturing and R&D facilities are located
in Yoqneam, Israel, with operating subsidiaries in the United States,
Germany, France, Japan, Australia and Singapore. For more information,
please visit http://www.givenimaging.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but are not
limited to, projections about our business and our future revenues,
expenses and profitability. Forward-looking statements may be, but are not
necessarily, identified by the use of forward-looking terminology such as
"may," "anticipates," "estimates," "expects," "intends," "plans,"
"believes," and words and terms of similar substance. Forward-looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the actual events, results, performance, circumstances or
achievements of the Company to be materially different from any future
events, results, performance, circumstances or achievements expressed or
implied by such forward-looking statements. Factors that could cause actual
events, results, performance, circumstances or achievements to differ from
such forward-looking statements include, but are not limited to, the
following: (1) our ability to develop and bring to market new products, (2)
our ability to receive regulatory clearance or approval to market our
products or changes in regulatory environment, (3) our success in
implementing our sales, marketing and manufacturing plans, (4) protection
and validity of patents and other intellectual property rights, (5) the
impact of currency exchange rates, (6) the effect of competition by other
companies, (7) the outcome of significant litigation, (8) our ability to
obtain reimbursement for our product from government and commercial payors,
(9) quarterly variations in operating results, (10) the possibility of
armed conflict or civil or military unrest in Israel, (11) the impact of
global economic conditions, and (12) other risks and factors disclosed in
our filings with the U.S. Securities and Exchange Commission, including,
but not limited to, risks and factors identified under such headings as
"Risk Factors," "Cautionary Language Regarding Forward-Looking Statements"
and "Operating Results and Financial Review and Prospects" in the Company's
Annual Report on Form 20-F for the year ended December 31, 2008. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. Except for the
Company's ongoing obligations to disclose material information under the
applicable securities laws, it undertakes no obligation to release publicly
any revisions to any forward-looking statements, to report events or to
report the occurrence of unanticipated events.